Gender | With reference to female [22, 23] | Female OR 0.62, CI 0.32–1.20, p-value 0.16 [22] OR 1.81, CI 0.97–3.44, p-value 0.06 [23] With significant fatigue (59.2% male), without significant fatigue (67% male), p-value > 0.05 [21] |
Age | | OR 1, CI 0.97–1.03, p-value 0.99 [22] OR 0.99, CI 0.97–1.02, p-value 0.89 [23] With significant fatigue (mean: 50.4, SD: 12.7), without significant fatigue (mean: 51.6, SD: 12), p-value > 0.05 [21] |
Disease Duration | | OR 1.00, CI 0.96–1.05, p-value 0.94 [22] OR 1.00, CI 0.97–1.03, p-value 0.90 [23] With significant fatigue (median: 4, IQR: 2–10), without significant fatigue (median: 5, IQR: 2–10), p-value > 0.05 [21] |
Education | With reference to primary school [22] For each year less of education [23] | Middle school: OR 0.24, CI 0.10–0.59, p-value < 0.01, high school and above: OR 0.23 CI 0.01–0.51, p-value < 0.01 [22] OR 1.09, CI 1.02–1.23, p-value 0.02 [23] |
Tender joints | For each 5 extra joints [23] | OR 1.30, CI 1.01–1.68, p-value 0.05 [23] |
Swollen joints | | OR 1.04, CI 0.94–1.14, p-value 0.43 [23] OR 1.034, CI 0.82–1.30, p-value 0.77 [22] |
Skin PsO | Skin PsO > 5% of body surface [23] | OR 4.67, CI 1.05–20.72, p-value 0.04 [23] |
Axial involvement | Current inflammatory back pain considered related to the inflammatory rheumatism [23] | OR 0.98, CI 0.51–1.87, p-value 0.94 [23] |
Enthesitis | Enthesitis count [22] Current inflammatory entheseal disease considered related to the inflammatory rheumatism [23] Leeds Enthesitis Index [21] | OR 1.04, CI 0.90–1.19, p-value 0.62 [22] OR 1.53, CI 0.76–3.05, p-value 0.23 [23] With significant fatigue (median: 0, IQR: 0–1), without significant fatigue (median: 0), p-value > 0.05 [21] |
Dactylitis | Current diffuse swelling of a digit considered related to the inflammatory rheumatism [21] | OR 0.56, CI 0.23–1.37, p-value 0.20 [23] With significant fatigue (median: 0, IQR: 0–3), without significant fatigue (median: 0, IQR: 0–1), p-value > 0.05 [21] |
DAPSA | | With significant fatigue (median: 18.3, IQR: 11.4–29.9), without significant fatigue (median: 11.3, IQR: 5.3–18), p-value < 0.01 [21] OR 0.89, CI 0.76–1.14, p-value 0.94 [22] |
PASI | | With significant fatigue (median: 4.2, IQR: 1.2–10.7), without significant fatigue (median: 2.1, IQR: 0.3–5.6), p-value 0.04 [21] |
MDA | Satisfying five out of of seven of the following: tender joint count ≤ 1, swollen joint count ≤ 1, enthesitis count ≤ 1, PASI ≤ 1 or body surface area ≤ 3, PtGA ≤ 20 mm, patient pain VAS ≤ 15 mm, and health assessment questionnaire ≤ 0.5 [22] | OR 1.00, CI 0.42–2.40, p-value 0.99 [22] |
VLDA | Satisfying seven out of of seven of the following: tender joint count ≤ 1, swollen joint count ≤ 1, enthesitis count ≤ 1, PASI ≤ 1 or body surface area ≤ 3, PtGA ≤ 20 mm, patient pain VAS ≤ 15 mm, and health assessment questionnaire ≤ 0.5 [22] | OR 0.161, CI 0.03, 0.92, p-value 0.04 [22] |
Medication use | Including cDMARDs, MTX, SSZ, LEF, CsA, ACT, biologics [21] | p-value > 0.05 [21] |
PsO Duration | | With significant fatigue (median: 12, IQR: 10–23), without significant fatigue (median: 14, IQR: 7–22), p-value > 0.05 [21] |
HAQ | HAQ [22] HAQ-DI [21] | OR 2.06, CI 0.55–7.76, p-value 0.29 [22] With significant fatigue (median: 0.75, IQR: 0.03–1.13), without significant fatigue (median: 0, IQR: 0 -0.38), p-value > 0.05 [21] |
Diabetes mellitus | | With significant fatigue (diabetes mellitus: 14.3%), without significant fatigue (diabetes mellitus: 19.2%), p-value > 0.05 [21] |
Ischemic heart disease | | With significant fatigue (ischemic heart disease: 4.1%), without significant fatigue (ischemic heart disease: 4.4%), p-value > 0.05 [21] |
Renal function | Creatinine clearance [21] | With significant fatigue (median: 89, IQR: 76–120), without significant fatigue (median: 94, IQR: 78–110), p-value > 0.05 [21] |
BMI | | With significant fatigue (mean: 24.8, SD: 5.5), without significant fatigue (mean: 24.9, SD: 3.9), p-value > 0.05 [21] OR 0.95, CI 0.90–1.01, p-value 0.09 [22] |
Inflammatory markers | CRP [22] ESR and CRP [21] | CRP: OR 1.01, CI 0.98–1.04, p-value 0.67 [22] ESR: With significant fatigue (median: 18, IQR: 11–47), without significant fatigue (median: 20, IQR: 10–35), p-value > 0.05 [21] CRP: With significant fatigue (median: 4.6, IQR: 3.1–11.1), without significant fatigue (median: 11.3, IQR: 3.1–9.5), p-value > 0.05 [21] |
VAS Pain | VAS, 0-100 mm [21, 22] | OR 1.02, CI 0.98–1.05, p-value 0.33 [22] With significant fatigue (median: 50, IQR: 15–70), without significant fatigue (median: 10, IQR: 0–43), p-value > 0.05 [21] |
Quality of life | PsAQoL [22] General health VAS [21] | OR 1.05, CI 0.95–1.16, p-value 0.03 [22] With significant fatigue (median: 60, IQR: 40–80), without significant fatigue (median: 40, IQR: 20–60), p-value > 0.05 [21] |
Fibromyalgia | FiRST [22] | OR 1.408, CI 1.09–1.82, p-value 0.01 [22] |
BASDAI | | OR 1.532, CI 1.15–2.04, p-value < 0.01 [22] |
Anxiety | HAD-A [22] | OR 1.135, CI 1.02–1.26, p-value 0.02 [22] |